SynZyme Technologies

SynZyme Technologies is a clinical-stage biotechnology company focused on the development of synthetic enzyme mimetics, or "SynZymes," to treat diseases driven by oxidative stress. The company's core technology involves small molecule catalytic antioxidants that replicate the functions of essential protective enzymes like superoxide dismutase and catalase. Unlike traditional antioxidants that are consumed in a 1:1 reaction, SynZymes act catalytically to neutralize thousands of reactive oxygen species molecules, providing sustained protection. The company's primary therapeutic focus includes ophthalmology, specifically dry eye syndrome, as well as radiation protection and neurodegeneration. SynZyme's lead candidate, SYN-101, has been evaluated in clinical trials for its potential to reduce inflammation and oxidative damage in the eye.